Adcetris

Active Ingredient(s): Brentuximab Vedotin
FDA Approved: * August 19, 2011
Pharm Company: * SEATTLE GENETICS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Adcetris Overview

Brentuximab vedotin (INN, trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T cell non-Hodgkin lymphoma).[1] Contents 1 Approvals and indications 1.1 Approval In Australia 2 Design 3 Clinical trials 4 Serious adverse events 4.1 ...

Read more Adcetris Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brentuximab_vedotin

Recent Adcetris Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Brentuximab Vedotin
  • Injection: 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Adcetris: (1 result)

Sorted by National Drug Code
  • 51144-050 Adcetris 50 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution by Seattle Genetics, Inc.

Other drugs which contain Brentuximab Vedotin or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA